Atlas Trials

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Clinical trial NCT03404193 · TERMINATED

Trial details

NCT number
NCT03404193
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myelomonocytic LeukemiaMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Chronic Myelomonocytic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia
Start date
2018-01-18
Primary completion
2026-03-05
Enrollment
235

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.